
    
      354 patients were enrolled in this study. Only 88 patients completed the study.

      For those patients completing the three years of data collection, 10% were considered
      Castrate Resistant and remained on EligardÂ®. For those patients not completing 3 years of
      follow-up, 8.8% were considered Castrate Resistant and did not continue in the study.
    
  